Google
OPK Stock Price & Analysis — Opko Health Inc (Healthcare >> Diagnostics & Research)
OPK FAQ
What is OPK's P/E ratio?
Opko Health Inc (OPK) currently trades at a P/E ratio of 45.54.
What is OPK's ROE?
Opko Health Inc reports a Return on Equity (ROE) of -6.16%.
What is OPK's dividend yield?
Opko Health Inc offers a dividend yield of 0.00%.
What is OPK's Quality Score?
Our AI rates OPK's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OPK?
Our AI Timing Score for OPK is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OPK belong to?
Opko Health Inc is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
OPK AI Analysis Summary
Our AI summary for OPK: Opko Health Inc (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 45.54, ROE of -6.16%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.31
Price
-0.01
(-0.76%)
Day Change
|
|
|---|
OPK, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.31 |
| PBV / Sector |
0.83 / 124.84
GREAT
|
| Earning Per Share | -0.10 |
| PE / Sector |
45.54 / 45.90
|
| PEG or PE/Growth / Sector |
0.77 / 1.50
|
| Average 1M Daily Value |
6.87 M
|
| Average 1W Daily Value |
16.74 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:57 |
| Symbol | OPK |
| Name | OPKO HEALTH INC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 746.33 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 985.15 / 36,121.22 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4400 Biscayne Boulevard, Miami, FL, United States, 33137
Phone: 305 575 4100
Website: https://www.opko.com
Employees: 2,275
Description: OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
